Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains.
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Overview
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains.
On June 11, 2026, David Scott Moore, acquired the direct acquisition of 21,700 common shares via option exercise, according to a June 15 SEC Form 4 filing.
Details
Transaction value based on SEC Form 4 weighted average purchase price ($11.53); post-transaction value based on June 11, 2026 market close ($11.60).
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
